CYP2W1 and adrenal cortex carcinoma: We did not observe any relationship between the CYP2W1 expression and the response to cytotoxic drugs, but surprisingly we found a significant impact of CYP2W1 levels on the efficacy of the therapy with mitotane, which is the only drug currently approved for the treatment of advanced ACC.